Artelo Biosciences, Inc. (ARTL): Price and Financial Metrics


Artelo Biosciences, Inc. (ARTL)

Today's Latest Price: $1.14 USD

0.00 (0.00%)

Updated Jan 25 4:00pm

Add ARTL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

ARTL Stock Price Chart Interactive Chart >

Price chart for ARTL

ARTL Price/Volume Stats

Current price $1.14 52-week high $4.42
Prev. close $1.14 52-week low $0.45
Day low $1.04 Volume 3,943,400
Day high $1.23 Avg. volume 4,327,053
50-day MA $0.72 Dividend yield N/A
200-day MA $0.98 Market Cap 17.91M

Artelo Biosciences, Inc. (ARTL) Company Bio


Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.


ARTL Latest News Stream


Event/Time News Detail
Loading, please wait...

ARTL Latest Social Stream


Loading social stream, please wait...

View Full ARTL Social Stream

Latest ARTL News From Around the Web

Below are the latest news stories about Artelo Biosciences Inc that investors may wish to consider to help them evaluate ARTL as an investment opportunity.

Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK Awarded Mitacs Accelerate GrantLA JOLLA, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2020 and provided a business update.“During the first quarter of fiscal 2021 we received both the Ethics approval and the Clinical Trials Authorization (CTA) in the United Kingdom for the Cancer Appetite Recovery Study (CAReS) for our lead drug candidate, ART27.13, a high-pote...

Yahoo | January 14, 2021

Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. A webcast of Artelo's presentation will be available on-demand as of 6:00 a.m. EDT, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Artelo's website at https://ir.artelobio.com/.About Artelo BiosciencesArtelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting end...

Yahoo | January 5, 2021

Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020.  “Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” commented Connie Matsui, chairperson of Artelo’s Board of Directors.  “We are grateful and excited to welcome him to the Board.” Dr. Reyes brings 35 years of experience in biotec...

Yahoo | December 2, 2020

U.K. Authorizes Artelo To Test Cancer Appetite Recovery Study Using Synthetic Cannabinoid

Artelo Biosciences Inc. (NASDAQ: ARTL ), a San Diego, California, and Dublin, Ireland-based clinical-stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system, announced on Monday it received a Clinical Trial Authorization (CTA) in the U.K. for its Cancer Appetite Recovery Study (CAReS). The study will look into ART27.13, a highly potent, peripherally restricted synthetic, dual G protein-coupled receptor agonist believed to target peripheral CB1/CB2 receptors in the endocannabinoid system, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca plc (NASDAQ: AZN ), ART27.13 has been in five Phase 1 clinical studies including over 200 subjects, where it demon...

Benzinga | November 19, 2020

Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th

LA JOLLA, CA / ACCESSWIRE / November 11, 2020 / Artelo Biosciences, Inc.

Yahoo | November 11, 2020

Read More 'ARTL' Stories Here

ARTL Price Returns

1-mo N/A
3-mo 121.14%
6-mo -2.56%
1-year -47.95%
3-year N/A
5-year N/A
YTD 56.16%
2020 -72.96%
2019 -60.87%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6622 seconds.